Kala Pharmaceuticals, Inc. (KALA)
NASDAQ: KALA · IEX Real-Time Price · USD
6.76
-0.07 (-1.02%)
At close: Jul 19, 2024, 4:00 PM
6.68
-0.08 (-1.18%)
Pre-market: Jul 20, 2024, 9:27 AM EDT
Company Description
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.
The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Kala Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Mark T. Iwicki |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781-996-5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark T. Iwicki | Chairman and Chief Executive Officer |
| Todd Bazemore | President and Chief Operating Officer |
| Dr. Kim Brazzell Ph.D. | Head of Research & Development and Chief Medical Officer |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Mary Reumuth CPA | Chief Financial Officer and Treasurer |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Eric L. Trachtenberg | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 144 | Filing |
| Jul 16, 2024 | 144 | Filing |
| Jul 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 28, 2024 | D | Notice of Exempt Offering of Securities |
| Jun 28, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 24, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |